Skip to main content
Premium Trial:

Request an Annual Quote

NGS Technology Firm Stratos Genomics Raises $10M

NEW YORK (GenomeWeb) – Stratos Genomics has raised $10 million toward a Series B financing round targeting $16.3 million.

The Seattle-based firm disclosed the raise in a Form D filed with the US Securities and Exchange Commission on Monday. In an email to GenomeWeb Daily News, Stratos Chairman and CEO Alan Stephan said the $10 million is the first close of a Series B round. He declined to comment further, saying more information will be released after the second close is completed.

In March, the firm told In Sequence that the Series B funding would go toward the development of a low-cost sequencing platform that combines the speed and throughput of nanopores with improved resolution and signal to noise, both for targeted and whole-genome sequencing.

Stratos was founded in 2007 as a spinout of engineering firm the Stratos Group. It raised $4 million in a Series A financing round in 2010 and garnered another $2.1 million in 2011 and $2 million in 2012 after it demonstrated that it was able to sequence a 36-base DNA template. Investors added a $2 million infusion last year after Stratos showed it could generate a 210-base read.

Stratos' technology, called sequencing by expansion, or SBX, converts DNA into a larger surrogate molecule containing reporter molecules that represent the DNA bases and generate a stronger signal, as company officials described to In Sequence. The surrogate molecule then passes through a nanopore with a detector to read out the signal, which is translated back into DNA sequence.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.